Quotes: MENA   Enter Symbol: NewsLetter: Search: advanced

Server is busy please try again later.  Join our daily free Newsletter

MENAFN Press - 17/10/2012
No. of Ratings : 0
Add to Mixx!



Due to technical reasons, this story has been removed from our database.

About CytoDyn Inc
CytoDyn is a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses and other antibody applications. Its proprietary drug candidate Cytolin(R) is a monoclonal antibody that binds to CD11a, a cellular antigen that is a component of the cellular adhesion molecule LFA-1. CytoDyn intends to explore the clinical development of Cytolin(R) for persons infected with the Human Immunodeficiency Virus ('HIV") to determine if it could perturb the natural course of HIV infection. CytoDyn recently completed a humanized antibody construct of Cytolin(R), filed a provisional patent for its use, and manufacturing discussions are underway. In addition, CytoDyn is exploring the possible application of its existing proprietary monoclonal antibody for the treatment of Feline Immunodeficiency Virus ("FIV"), a retroviral infection in cats. CytoDyn recently filed for a provisional patent for the use of these antibodies as well as selected small molecule antagonists and agonists for the treatment of FIV, and filed an application for registration of the trademark CytoFeline, intended for use in conjunction with veterinary preparations for the treatment of FIV. For more information about Cytolin(R), CytoFeline(TM) and CytoDyn please go to www.cytodyn.com.Forward-Looking StatementsThis press release includes forward-looking statements and forward-looking information within the meaning of United States securities laws. These statements and information represent CytoDyn's intentions, plans, expectations and beliefs, and are subject to risks, uncertainties and other factors, of which many are beyond CytoDyn's control. These factors could cause actual results to differ materially from such forward-looking statements or information. The words "believe," "estimate," "expect," "intend," "attempt," "anticipate," "foresee," "plan," and similar expressions and variations thereof, identify certain of such forward-looking statements or forward-looking information, which speak only as of the date on which they are made. CytoDyn disclaims any intention or obligation to publicly update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements or forward-looking information.While it is impossible to identify or predict all such matters, these differences may result from, among other things, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and product candidates, including the risks that clinical trials will not commence or proceed as planned; products appearing promising in early trials will not demonstrate efficacy or safety in larger-scale trials; future clinical trial data on our products and product candidates will be unfavorable; our products will not receive marketing approval from regulators or, if approved, fail to gain sufficient market acceptance to justify development and commercialization costs; competing products currently on the market or in development may reduce the commercial potential of our products; CytoDyn, our collaborators or others may identify side effects after the product is on the market; or efficacy or safety concerns regarding marketed products, whether or not scientifically justified, may lead to product recalls, withdrawals of marketing approval, reformulation of the product, additional pre-clinical testing or clinical trials, changes in labeling of the product, the need for additional marketing applications, or other adverse events.We are also subject to additional risks and uncertainties, including risks associated with the actions of our corporate, academic and other collaborators and government regulatory agencies; risks from market forces and trends; potential product liability; intellectual property, litigation, environmental and other risks; and risks that current and pending patent protection for our products may be invalid, unenforceable or challenged, or fail to provide adequate market exclusivity. There are also substantial risks arising out of our need to raise additional capital to develop our products and satisfy our financial obligations; the highly regulated nature of our business, including government cost-containment initiatives and restrictions on third-party payments for our products; the highly competitive nature of our industry; and other factors set forth in our Annual Report on Form 10-K and other reports filed with the U.S. Securities and Exchange Commission.

 


MENAFN Press




  MENA News Headlines
 Jul 1 2016 - Qatar, Indonesia join forces in gas searchMENAFN
(MENAFN) Indonesia is seeking partnership with Qatari top firms such as Qatar Petroleum or RasGas for gas exploration on its land, based on recent reports.Indonesia already sees and realizes the ...

 Jul 1 2016 - UAE seeks for India to be top business partnerMENAFN
(MENAFN) India is forecasted to surpass Japan as the top export destination of the UAE by the year 2030, according to the latest reports.Japan and India stood at 11 percent and 6 percent respectively ...

 Jul 1 2016 - Omani Port of Salalah initiates new crucial line servicesMENAFN
(MENAFN) Oman's Port of Salalah, a key Arab Gulf region gateway port for the Arabian Sea, is going to have French-based CMA CGM, the world's third-largest container shipping line adding two new ...

 Jul 1 2016 - Kuwait oil price up 54 cents to USD44.66 pbKuwait News Agency (KUNA)
(MENAFN - Kuwait News Agency (KUNA)) KUWAIT, July 1 (KUNA) -- The price of Kuwait oil went up by 54 cents to reach USD 44.66 per barrel Thursday after trading at USD 44.12 pb the day before, said ...

 Jul 1 2016 - Sabbiyah shrimp project to achieve production boom - studyKuwait News Agency (KUNA)
(MENAFN - Kuwait News Agency (KUNA)) KUWAIT, July 1 (KUNA) -- The proposed Sabbiyah shrimp farming project expected to be a leading one is designed to achieve a production boom to meet the rising ...

 Jul 1 2016 - Kuwait- No makeshift eid prayer locations -- ministryKuwait News Agency (KUNA)
(MENAFN - Kuwait News Agency (KUNA)) KUWAIT, July 1 (KUNA) -- Eid Al-Fitr prayers will be confined to mosques and no makeshift prayer places will be set up, the Ministry of Awqaf and Islamic Affairs ...

 Jul 1 2016 - Kuwait- His Highness the Amir congratulates Rwanda on nat'l dayKuwait News Agency (KUNA)
(MENAFN - Kuwait News Agency (KUNA)) KUWAIT, July 1 (KUNA) -- His Highness the Amir Sheikh Sabah Al-Ahmad Al-Jaber Al-Sabah sent a cable of congratulations Friday to Rwanda''s President Paul Kagame ...

 Jul 1 2016 - Kuwait- His Highness the Amir congratulatesc Canada on nat'l dayKuwait News Agency (KUNA)
(MENAFN - Kuwait News Agency (KUNA)) KUWAIT, July 1 (KUNA) -- His Highness the Amir Sheikh Sabah Al-Ahmad Al-Jaber Al-Sabah sent a cable of congratulations Friday to General Governor of Canada David ...

 Jul 1 2016 - Kuwait- His Highness the Amir congratulates Burundi on nat'l dayKuwait News Agency (KUNA)
(MENAFN - Kuwait News Agency (KUNA)) KUWAIT, July 1 (KUNA) -- His Highness the Amir Sheikh Sabah Al-Ahmad Al-Jaber Al-Sabah sent a cable of congratulations Friday to Burundi''s President Pierre ...

 Jul 1 2016 - Saudi Arabia condemns Bahrain blastKuwait News Agency (KUNA)
(MENAFN - Kuwait News Agency (KUNA)) JEDDAH, July 1 (KUNA) -- Saudi Arabia has condemned "the terrorist act" that happened in eastern Bahrain killing a woman and injuring her children. The official ...

more...


 





Google

 
 

Middle East North Africa - Financial Network

MENAFN News Market Data Countries Tools Section  
 

Middle East North Africa - Financial Network
Arabic MENAFN

Main News
News By Industry
News By Country

Islamic Finance News
Private Equity News

How-To Guides
Technology Section

Travel Section

Search News

Market Indices
Quotes & Charts

Global Indices
Arab Indices

Commodoties

Oil & Energy

Currencies Cross Rates
Currencies Updates
Currency Converter

USA Stocks
Arab Stocks
 

Algeria 
Bahrain 
Egypt 
Iraq
Jordan 
Kuwait 
Lebanon
Morocco 
Oman 
Palestine
Qatar 
Saudi Arabia 
Syria
Tunisia 
UAE 
Yemen

Weather
Economic Calendar
Financial Glossary


Financial Calculators

RSS Feeds [XML]

Corporate Monitor

Events

Real Estate
Submit Your Property

Arab Research
Buy a Research

Press Releases
Submit your PR

Join Newsletters


 
© 2014 menafn.com All Rights Reserved.  Terms of Service | Privacy Policy | Contact Us | Advertise | About MENAFN | Career Opportunities | Feedback | Help